370 related articles for article (PubMed ID: 30724767)
1. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
Darweesh SK; Gad AA; Akroof K; ElLatif ZA
Eur J Gastroenterol Hepatol; 2019 May; 31(5):607-612. PubMed ID: 30724767
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
[TBL] [Abstract][Full Text] [Related]
5. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
[TBL] [Abstract][Full Text] [Related]
6. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
Choudhary NS; Saraf N; Saigal S; Mohanka R; Rastogi A; Goja S; Menon PB; Soin AS
Transpl Infect Dis; 2015 Jun; 17(3):329-33. PubMed ID: 25682715
[TBL] [Abstract][Full Text] [Related]
7. A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients.
Chen G; Liu H; Hu ZQ; Bai JH; Liu QY; Zhao YP; Gan XM; Wang F; Wang DD; Ma LJ; Li L
Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):901-6. PubMed ID: 26011237
[TBL] [Abstract][Full Text] [Related]
8. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA
Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595
[TBL] [Abstract][Full Text] [Related]
9. Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients.
Radhakrishnan K; Chi A; Quan DJ; Roberts JP; Terrault NA
Transplantation; 2017 Sep; 101(9):2079-2082. PubMed ID: 28880197
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B Immunoglobulin discontinuation in long-term liver transplant patients.
Dobrindt EM; Keshi E; Salim Y; Gillespie A; Saipbaev A; Schöning W; Öllinger R; Pratschke J; Eurich D
Transpl Infect Dis; 2020 Aug; 22(4):e13303. PubMed ID: 32367631
[TBL] [Abstract][Full Text] [Related]
11. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
[TBL] [Abstract][Full Text] [Related]
12. Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation.
Na GH; Kim DG; Han JH; Kim EY; Lee SH; Hong TH; You YK; Choi JY
J Gastroenterol Hepatol; 2014 Jan; 29(1):151-6. PubMed ID: 24117684
[TBL] [Abstract][Full Text] [Related]
13. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
[TBL] [Abstract][Full Text] [Related]
14. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
[TBL] [Abstract][Full Text] [Related]
15. Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative.
Geng L; Lin BY; Shen T; Guo H; Ye YF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):316-8. PubMed ID: 27298109
[TBL] [Abstract][Full Text] [Related]
16. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal.
Manini MA; Whitehouse G; Bruce M; Passerini M; Lim TY; Carey I; Considine A; Lampertico P; Suddle A; Heaton N; Heneghan M; Agarwal K
Dig Liver Dis; 2018 Sep; 50(9):944-953. PubMed ID: 29735294
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.
Cholongitas E; Goulis J; Akriviadis E; Papatheodoridis GV
Liver Transpl; 2011 Oct; 17(10):1176-90. PubMed ID: 21656655
[TBL] [Abstract][Full Text] [Related]
18. A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients.
Manini MA; Bruce M; Whitehouse G; Mazzarelli C; Considine A; Agarwal K; Suddle A; Fagiuoli S; Heaton N; Heneghan M
Transplant Proc; 2021; 53(1):207-214. PubMed ID: 32605776
[TBL] [Abstract][Full Text] [Related]
19. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
Idilman R; Akyildiz M; Keskin O; Gungor G; Yilmaz TU; Kalkan C; Dayangac M; Cinar K; Balci D; Hazinedaroglu S; Tokat Y
Clin Transplant; 2016 Oct; 30(10):1216-1221. PubMed ID: 27409074
[TBL] [Abstract][Full Text] [Related]
20. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]